CD274 and urinary bladder cancer: Based on this study, atezolizumab was approved in May of 2016 under an accelerated approval pathway for platinum refractory bladder cancers (Cohort II) independent of PD-L1 status even though the overall response rates were more favorable in those patients who had PD-L1 staining in  ≥ 5% in immune cells (IC2/3).